FBXW7 and chronic myelogenous leukemia, BCR-ABL1 positive: On the contrary, Takeishi et al. suggested that expression of FBXW7 has implications in cancer drug resistance and that ablation of FBXW7 in combination with anti-cancer drugs might be a promising therapeutic strategy for chronic myeloid leukemia (CML) patients.